Alkermes Plc (ALKS NASDAQ) stock market data APIs
$30.4881
-0.11(-0.4%)
as of October 17, 2025
Try our APIs with
free plan!
Alkermes Plc Financial Data Overview
Price chart is built with
Anychart
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Prev. Close
30.4881
Open
30.3826
High
31.4362
Low
30.0409
52 wk Range
25.165-36.45
Market Cap
4 995 M
P/E Ratio
14.6184
Shares Outstanding
165 M
Revenue
1 505 M
EPS
0
Beta
0.492
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Alkermes Plc (top by weight)
Ticker
100-day Price Change
Weight
POAGX.US
PRIMECAP ODYSSEY AGGRESSIVE GROWTH FUND PRIMECAP ODYSSEY AGGRESSIVE GROWTH FUND
6.92
(14.74%)
2.34
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alkermes Plc data using free add-ons & libraries
Get Alkermes Plc Fundamental Data
Alkermes Plc Fundamental data includes:
- Net Revenue: 1 505 M
- EBITDA: 403 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-23
- EPS/Forecast: 0.38
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alkermes Plc News
New
Do Options Traders Know Something About Alkermes Stock We Don't?
Investors in Alkermes plc ALKS need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 17, 2025 $23 Put had some of the highest implied volatility...
Deutsche Bank’s ‘Conviction list’ for Q4: KO, SCHW, LLY and more
[Journey of Distinction - Gradient Spheres Tapering Along Steps to a Singular Summit] J Studios/DigitalVision via Getty Images Deutsche Bank’s research team selected their top investment ideas to h...
Alkermes (ALKS) Shares Cross Above 200 DMA
In trading on Wednesday, shares of Alkermes plc (Symbol: ALKS) crossed above their 200 day moving average of $25.99, changing hands as high as $26.21 per share. Alkermes plc shares are currently trad...
Is Alkermes' (ALKS) Narcolepsy Drug Breakthrough Shifting Its Investment Narrative?
In late September 2025, RBC Capital upgraded Alkermes following promising phase 2 results for its drug candidate alixorexton in narcolepsy type 1, which showed clinically meaningful efficacy and surpa...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
